



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/982,763	10/18/2001	Ruth Elinor Bauhahn	11738.00039	8709
22908 7	590 01/13/2005		EXAMINER	
BANNER & WITCOFF, LTD.			BOCKELMAN, MARK	
	WACKER DRIVE			
SUITE 3000			ART UNIT	PAPER NUMBER
CHICAGO, IL	2 60606		3762	
			DATE MAIL ED: 01/12/2001	-

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	7			
Office Action Summary		09/982,763	BAUHAHN ET AL.				
		Examin r	Art Unit				
		Mark W Bockelman	3762				
Period f	Th MAILING DATE of this communication Reply	on appears on the cover sheet w	th the corr spond nce address	; 			
THE - Exte afte - If th - If NO - Fail Any	HORTENED STATUTORY PERIOD FOR F MAILING DATE OF THIS COMMUNICAT ensions of time may be available under the provisions of 37 (r SIX (6) MONTHS from the mailing date of this communicat e period for reply specified above is less than thirty (30) days o period for reply is specified above, the maximum statutory ure to reply within the set or extended period for reply will, by reply received by the Office later than three months after the ned patent term adjustment. See 37 CFR 1.704(b).	TION. CFR 1.136(a). In no event, however, may a rion. s, a reply within the statutory minimum of thin period will apply and will expire SIX (6) MON ristatute, cause the application to become AB	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communi BANDONED (35 U.S.C. § 133).	ication.			
Status			•				
1)⊠	Responsive to communication(s) filed on	20 October 2004.					
		This action is non-final.					
3)	,						
	closed in accordance with the practice ur	nder <i>Ex par</i> te Quayle, 1935 C.D). 11, 453 O.G. 213.				
Disposit	tion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1-9,45 and 46 is/are pending in 4a) Of the above claim(s) is/are wi Claim(s) is/are allowed. Claim(s) 1-9, 45-46 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction	thdrawn from consideration.					
Applicat	tion Papers						
9)[The specification is objected to by the Ex	aminer.					
10))☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection	• • • • • • • • • • • • • • • • • • • •	• ,				
11)	Replacement drawing sheet(s) including the of the oath or declaration is objected to by the oath or declaration is objected to be	•	• • •	. ,			
Priority	under 35 U.S.C. § 119		•				
12)[a)	Acknowledgment is made of a claim for for All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International E	uments have been received. uments have been received in A e priority documents have been Bureau (PCT Rule 17.2(a)).	opplication No received in this National Stage	е			
Attachmer		_					
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-94		Summary (PTO-413) s)/Mail Date				
3) Infor	rmation Disclosure Statement(s) (PTO-1449 or PTO/ er No(s)/Mail Date	, I	nformal Patent Application (PTO-152)				

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-6, 8-9, 45 are rejected under 35 U.S.C. 102(b) as being anticipated by Ford Et al USPN 5,681,285. Ford teaches the storage of a library of drug delivery programs in a pump. Various drug programs can be called up and parameter settings which includes infusion rates, drug dosages (column 3 lines 12-15), as well as preprogrammed with an Auto Schedule function for start and stop times (column 13 line 65- column 14 line 8). After setting the parameters the new program be saved under a user specified file name for recall and usage. (see entire document- see column 12 41-60 for an example) A programmer, either the front display or a computer, may be used to store new drug programs.

Claims 1, 2, 7, 45, 46 are rejected under 35 U.S.C. 102(b) as being anticipated by Snell USPN 5,456,691. Snell teach a method of programming and using an implantable device with a telemetric external programmer. Various program modules 30 are stored within the implantable device, which may be called upon by the external programmer 12 to build new programs to be executed by the implanted device. The implantable device is stated to be an implantable pump (see column 7 lines 35-50)

which allows the physician to select various modules to create individual specific programs.

Response to Arguments

Applicant's arguments filed 10-20-2004 have been fully considered but they are not persuasive. With respect to Ford, et al. Ford teaches the same kinds of modifications as applicant to the accessed program in the library, I.e. it can be customized for drug delievery rates, body weights and other patient specific parameters. It is unclear to the examiner how applicant feels the claims define over the art when the art performes the same function. With respect to Snell, the addition of various blocks of instruction code (i.e the modules) will clearly modify the accessed program. The examiner again does not understand applicant's alleged point of distinction.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

Art Unit: 3762

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark W Bockelman whose telephone number is (703)-308-2112. The examiner can normally be reached on Monday - Thursday 10-8:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on (703) 308-5181. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MWB

January 9, 2005